Fourth Quarter R&D Costly For Sirtris, But Partner Could Be Near
This article was originally published in The Pink Sheet Daily
Executive Summary
New chemical entities’ potency lures would-be collaborators.
You may also be interested in...
GSK To Pay $720 Million For Sirtris
Independent unit will target diabetes and diseases of aging, deal crafter tells “The Pink Sheet” DAILY.
GSK To Pay $720 Million For Sirtris
Independent unit will target diabetes and diseases of aging, deal crafter tells “The Pink Sheet” DAILY.
Pharmion and MethylGene Collaborate On Sirtuin Inhibitors To Treat Cancer
MethylGene could get up to $79 million in milestones, 21 percent in U.S. royalties.